

Corporate Governance Report

(1) Company's Philosophy on Corporate Governance

The Company is committed to good Corporate Governance and believes that it is essential for achieving long-term corporate goals and to enhance stakeholders' value. The Company respects the rights of its shareholders to obtain information on the performance of the Company. The Company believes that best board practices, transparent disclosures and shareholder empowerment are necessary to maximize the long term value to the shareholders of the Company and to ensure that all stakeholders' interests are protected. The Company places great emphasis on principles such as empowerment and integrity of its employees, safety of the employees & communities surrounding our plants, transparency in decision making

process, fair & ethical dealings with all stakeholders and society in general. The Compliance Report on Corporate Governance herein signifies adherence by the Company of all mandatory requirements of Regulation 34(3) and Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

(2) Board of Directors

The Board has a balanced mix of Executive and Non-Executive Directors with two Independent Women Directors having rich experience and expertise.

The present strength of the Board of Directors of your Company is 12 (twelve).

Composition of the Board is in conformity with Regulation 17 of SEBI Listing Regulations read with Section 149 of the Companies Act, 2013 ("Act"). The names and categories of Directors are as follows:

Category	Name of Directors	Inter-se relationship between Directors
Promoter, Non-Executive and Non-Independent Director	[#] Late Mr. Samprada Singh (Chairman Emeritus)	Father of Mr. Balmiki Prasad Singh and Grandfather of Mr. Sandeep Singh and Mr. Sarvesh Singh
Promoter Executive Directors	Mr. Basudeo N. Singh (Executive Chairman)	Father of Mr. Dhananjay Kumar Singh and Mr. Mritunjay Kumar Singh
	Mr. Sandeep Singh (Managing Director)	Grandson of Late Mr. Samprada Singh and Brother of Mr. Sarvesh Singh
	Mr. Dhananjay Kumar Singh (Joint Managing Director)	Son of Mr. Basudeo N. Singh and Brother of Mr. Mritunjay Kumar Singh
	Mr. Balmiki Prasad Singh (Executive Director)	Son of Late Mr. Samprada Singh
	Mr. Mritunjay Kumar Singh (Executive Director)	Son of Mr. Basudeo N. Singh and Brother of Mr. Dhananjay Kumar Singh
	[*] Mr. Sarvesh Singh (Executive Director)	Grandson of Late Mr. Samprada Singh and Brother of Mr. Sandeep Singh
	Non-Executive Independent Directors	[§] Mr. Akhouri Maheshwar Prasad
Mr. Ranjal Laxmana Shenoy		N.A.
Mr. Arun Kumar Purwar		N.A.
Ms. Sangeeta Singh		N.A.
Ms. Sudha Ravi		N.A.
Dr. Dheeraj Sharma		N.A.
	^{&} Mr. Narendra Kumar Aneja	N.A.

[#]Demise: 27th July, 2019

^{*}Appointment: 11th November, 2019

[§]Completion of Tenure: 15th March, 2020

[&]Appointment: 16th March, 2020



Core Skills / Expertise / Competence for the Board of Directors

Detailed below are the core skills / expertise /competencies required for the effective functioning of our Company alongwith specific expertise of the Board of the Directors of the Company:

Name of Director	Areas of Core Skills/Expertise/Competence							
	Financial Skills/ Controls	Pharma domestic and international marketing strategy	Legal and Regulatory Compliance and Governance	Risk Management	Plant Management	Human Resource/ Leadership	M&A	Supply Chain
Mr. Basudeo N Singh, Executive Chairman	√	√	√	√	√	√	√	√
Mr. Sandeep Singh, Managing Director	√	√	√	√	√	√	√	√
Mr. Dhananjay Kumar Singh, Joint Manager Director	√	√	√	√		√		√
Mr. Mritunjay Kumar Singh, Executive Director	√	√		√	√			√
Mr. Balmiki Prasad Singh, Executive Director	√	√						√
Mr. Sarvesh Singh, Executive Director	√	√						
Mr. Ranjal Laxmana Shenoy, Independent Director	√		√					√
Mr. Arun Kumar Purwar, Independent Director	√		√	√				
Mr. Narendra Kumar Aneja, Independent Director	√		√	√				
Ms. Sangeeta Singh, Independent Director	√					√		
Ms. Sudha Ravi, Independent Director	√			√		√		
Dr. Dheeraj Sharma, Independent Director		√		√		√	√	√

The above marks against names of the Board Members signify their specific skill/ expertise/ competency in the above mentioned areas while all the Directors are having the sufficient skill and expertise to understand the operational issues of the Company.

Non-Executive / Independent Directors

As on 31st March, 2020, shareholding of Late Mr. Samprada Singh was 15,77,190 Equity Shares while Mr. Narendra Kumar Aneja, Independent Director held 57 Equity Shares of the Company. None of the other Non-Executive Directors held any Equity Shares of the Company as on 31st March, 2020.

In the opinion of the Board, the existing Independent Directors fulfill the conditions specified in the SEBI Listing Regulations and are independent of the Management.

During the year under review, the tenure of Mr. Akhouri Maheshwar Prasad as an Independent Director of the Company expired on 15th March, 2020 and Mr. Narendra Kumar Aneja has been appointed as an Independent Director w.e.f. 16th March, 2020 on the Board of Directors of the Company.

Board Meetings

7 (seven) Board Meetings were held during the year. The dates on which the Meetings were held during the year ended 31st March, 2020 are as follows:

05th April, 2019, 30th May, 2019, 04th June, 2019, 12th August, 2019, 11th November, 2019, 20th December, 2019 and 07th February, 2020.

Attendance of each Director at the Board Meetings, last AGM, number and names of other Directorships and number of Chairmanships/ Memberships of Committee(s) of each Director as on 31st March, 2020, are given below:

Name of Director	Attendance			*No. of other Committee Memberships / Chairmanships			Directorships in other Companies	
	Number of Board Meetings held during the Director's tenure	Number of Board Meetings attended	Last AGM held on 27 th August, 2019	#Committee Memberships	#Committee Chairmanships	*Other Directorships	Names of other listed entities where person is Director	Category of Directorship in the listed entities
^{&} Late Mr. Samprada Singh	3	2	NA	0	0	0	NA	NA
Mr. Basudeo N. Singh	7	7	Yes	0	0	1	NA	NA
Mr. Sandeep Singh	7	6	Yes	1	0	1	NA	NA
Mr. Dhananjay Kumar Singh	7	5	Yes	0	0	0	NA	NA
Mr. Balmiki Prasad Singh	7	3	No	0	0	0	NA	NA
Mr. Mritunjay Kumar Singh	7	7	Yes	1	0	1	NA	NA
[§] Mr. Sarvesh Singh	2	2	NA	0	0	0	NA	NA
[¶] Mr. Akhouri Maheshwar Prasad	7	7	Yes	1	0	1	NA	NA
Mr. Ranjal Laxmana Shenoy	7	6	Yes	4	1	3	1. Elantas Beck India Limited 2. Sunshield Chemicals Limited	Independent Director
Mr. Arun Kumar Purwar	7	7	No	3	2	5	1. Jindal Steel and Power Limited 2. IIFL Finance Limited (Formerly known as IIFL Holdings Limited) 3. Balaji Telefilms Limited	Independent Director
Ms. Sangeeta Singh	7	5	Yes	5	0	5	1. Accelya Kale Solutions Limited 2. S H Kelkar and Company Limited	Independent Director
Ms. Sudha Ravi	7	5	Yes	4	1	3	1. Goodyear India Limited	Independent Director
Dr. Dheeraj Sharma	7	6	Yes	0	0	0	NA	NA
[©] Mr. Narendra Kumar Aneja	0	0	NA	0	0	1	NA	NA

* The list does not include Directorships, Committee Memberships and Committee Chairmanships in Private Limited, Foreign and Section 8 Companies.

[#] The Committee Memberships and Chairmanships in other Companies include Memberships and Chairmanships of Audit and Stakeholders' Relationship Committees of public companies only.

[&] Demise: 27th July, 2019

[§] Appointment: 11th November, 2019

[¶] Completion of Tenure: 15th March, 2020

[©] Appointment: 16th March, 2020

Familiarization Programme

At the time of appointment, Independent Directors are made aware of their roles, rights and responsibilities through a formal letter of appointment which also stipulates the various terms and conditions of their engagement. The terms & conditions of the appointment of Independent Directors are posted pursuant to Regulation 46(2)(b) of the SEBI Listing Regulations, on the Company's website and can be accessed at https://www.alkemlabs.com/pdf/policies/996508366Terms_of_appointment-Independent_directors.pdf. At Board and Committee Meetings, the Independent Directors are on regular basis familiarized with the business model, regulatory environment in which Company operates, strategy, operations, functions, policies and procedures of the Company and its subsidiaries so that they are able to play a meaningful role in the overall governance processes of the Company. Independent Directors are briefed about the operations, quality control and quality assurance processes in the Company. The details of the Familiarization Programmes imparted by the Company to the Independent

Directors during the financial year have been uploaded on the Company's website, the web link for which is <https://www.alkemlabs.com/corporate-governance.php>.

(3) Code of Conduct

All the Directors and senior management have affirmed compliance with the Code of Conduct as approved and adopted by the Board of Directors and a declaration to that effect, signed by the Managing Director has been annexed to the Corporate Governance Report. The Code of Conduct has been posted on the website of the Company, the web link for which is https://www.alkemlabs.com/pdf/policies/824596594993521810CODE_OF_BUSINESS_CONDUCT_AND_ETHICS_FOR_SENIOR_MANAGEMENT.pdf

(4) Code for Prevention of Insider Trading

As per SEBI (Prohibition of Insider Trading) Regulations, 2015, ("Insider Trading Regulations") the Company has adopted Codes for Fair Disclosures and Conduct for Insider Trading ("Code") to deter the insider trading in the securities



of the Company based on the unpublished price sensitive information. The trading window is closed during the time of declaration of results and occurrence of any material event as per the Code for such duration as may be decided by the Compliance Officer. The Board of Directors have appointed Mr. Manish Narang, President – Legal, Company Secretary as Compliance Officer, who is responsible for setting forth procedures and implementation of the Code for trading in Company's securities. In line with the amendments introduced by SEBI in the Insider Trading Regulations, the Code was amended suitably during the year, to ensure due compliance with the Insider Trading Regulations and to align it with the amendments.

(5) Audit Committee

The constitution of the Audit Committee is in compliance with the provisions of Section 177 of the Act and Regulation 18 of the SEBI Listing Regulations.

During the year, 7 (seven) Audit Committee Meetings were held, viz. 05th April, 2019, 30th May, 2019, 04th June, 2019, 24th June, 2019, 12th August, 2019, 07th November, 2019 which was adjourned to 11th November, 2019 and 06th February, 2020. The intervening gap between two consecutive meetings was not more than one hundred and twenty days.

The present composition of the Audit Committee and attendance of Members during the year was as follows:

Name of the Director	Designation in the Committee	No. of Meetings held during the Member's tenure	No. of Meetings attended
Mr. Ranjal Laxmana Shenoy	Chairman	7	6
Ms. Sudha Ravi	Member	7	6
Ms. Sangeeta Singh	Member	7	7
*Mr. Akhouri Maheshwar Prasad	Member	7	7
Mr. Mritunjay Kumar Singh	Member	7	7
Mr. Sandeep Singh	Member	7	6
#Mr. Narendra Kumar Aneja	Member	NA	NA

*Member upto 15th March, 2020.

#Member from 16th March, 2020.

Mr. Manish Narang, President – Legal, Company Secretary and Compliance Officer is the Secretary of the Audit Committee.

Terms of reference of the Audit Committee

1. Oversight of the company's financial reporting process, examination of the financial statement and the auditors' report thereon and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
2. Providing recommendation for appointment, reappointment and replacement, remuneration and terms of appointment of auditors of the company and the fixation of audit fee;
3. Review and monitor the statutory auditor's independence and performance and effectiveness of audit process;
4. Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
5. Reviewing, with the management, the annual financial statements before submission to the board for approval, with particular reference to:
 - i. Matters required to be included in the 'Director's Responsibility Statement' to be included in the Board's report in terms of clause (c) of subsection 3 of Section 134 of the Companies Act, 2013, as amended;
 - ii. Changes, if any, in accounting policies and practices and reasons for the same;
 - iii. Major accounting entries involving estimates based on the exercise of judgment by management;
- iv. Significant adjustments made in the financial statements arising out of audit findings;
- v. Compliance with listing and other legal requirements relating to financial statements;
- vi. Disclosure of any related party transactions; and
- vii. Qualifications in the draft audit report.
6. Reviewing, with the management, the quarterly and half-yearly financial statements before submission to the Board for approval;
7. Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document/prospectus/ notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;
8. Reviewing, with the management, performance of statutory and internal auditors, and adequacy of the internal control systems;
9. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;

10. Discussion with internal auditors any significant findings and follow up there on;
 11. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;
 12. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
 13. Look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
 14. Review the functioning of the whistle blower mechanism;
 15. Approval of appointment of the chief financial officer (i.e., the whole time finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background etc. of the candidate;
 16. To investigate any activity within its terms of reference;
 17. To seek information from any employee;
 18. To obtain outside legal or other professional advice;
 19. To secure attendance of outsiders with relevant expertise, if it considers necessary;
 20. Approval or any subsequent modification of transactions of the company with related parties and omnibus approval for related party transactions proposed to be entered into by the Company subject to such conditions as may be prescribed;
 21. Scrutiny of inter-corporate loans and investments;
 22. Valuation of undertakings or assets of the company, wherever it is necessary;
 23. Evaluation of internal financial controls and risk management systems;
 24. To provide recommendation to the Board of Directors of the Company for declaration of Interim Dividend to be paid to the shareholders of the Company;
 25. Reviewing the utilization of loans and/or advances from / investment to the subsidiaries exceeding Rupees 100 Crores or 10% of the asset size of the subsidiary, whichever is lower including existing loans/ advances/ investments; and
 26. Carry out any other function as mentioned in the terms of reference of the Audit Committee.
- The Audit Committee mandatorily reviews the following:**
1. Management's discussion and analysis of financial condition and results of operations;
 2. Statement of significant related party transactions (as defined by the Audit Committee), submitted by the management;
 3. Management letters / letters of internal control weaknesses issued by the statutory auditors;
 4. Internal audit reports relating to internal control weaknesses;
 5. The appointment, removal and terms of remuneration of the chief internal auditor;
 6. Statement of deviations:
 - (a) quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).
 - (b) annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).

(6) Nomination and Remuneration Committee

The constitution of the Nomination and Remuneration Committee is in compliance with the provisions of Section 178 of the Act and Regulation 19 of the Listing Regulations.

During the year, 4 (four) Nomination and Remuneration Committee Meetings were held viz. 29th May, 2019, 7th November, 2019, 20th December, 2019 and 06th February, 2020.

The present composition of the Nomination and Remuneration Committee and attendance of Members in the Meetings during the year was as follows:

Name of the Director	Designation in the Committee	No. of Meetings held during the Member's tenure	No. of Meetings attended
Mr. Arun Kumar Purwar	Chairman	4	4
*Mr. Akhouri Maheshwar Prasad	Member	4	4
Mr. Basudeo N. Singh	Member	4	4
Ms. Sangeeta Singh	Member	4	4
#Mr. Ranjal Laxmana Shenoy	Member	NA	NA

*Member upto 15th March, 2020.

#Member from 16th March, 2020.



Terms of reference of the Nomination and Remuneration Committee

- (a) Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy, relating to the remuneration of the directors, key managerial personnel and other employees;
- (b) Formulation of criteria for evaluation of independent directors and the Board;
- (c) Devising a policy on Board diversity;
- (d) Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board their appointment and removal. The Company shall disclose the remuneration policy and the evaluation criteria in its Annual Report;
- (e) Determining whether to extend or continue the term of appointment of the independent directors, on the basis of the report of performance evaluation of independent directors;
- (f) Analysing, monitoring and reviewing various human resource and compensation matters;
- (g) Determining the company's policy on specific remuneration packages for executive directors including pension rights and any compensation payment, and determining remuneration packages of such directors;
- (h) Determining and recommending to the Board, all remuneration, in whatever form, payable to senior management of the Company and determining compensation levels payable to the other staff (as deemed necessary), which shall be market-related, usually consisting of a fixed and variable component;
- (i) Reviewing and approving compensation strategy from time to time in the context of the then current Indian market in accordance with applicable laws;
- (j) Performing such functions as are required to be performed by the compensation committee under the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;
- (k) Framing suitable policies and systems to ensure that there is no violation, by an employee of any applicable

laws in India or overseas, including [the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015] and the Securities and Exchange Board of India (Prohibition of Fraudulent and Unfair Trade Practices relating to the Securities Market) Regulations, 2003; and

- (l) Performing such other activities as may be delegated by the Board of Directors and/or are statutorily prescribed under any law to be attended to by the Nomination and Remuneration Committee.

Evaluation of Performance of Board, Committees and Directors

Pursuant to the provisions of the Act, the SEBI Listing Regulations and the Guidance Note issued by SEBI, the Nomination and Remuneration Committee of the Company evaluated the performance of individual Directors, Board as a whole and all the Committees of the Board on the basis of performance evaluation criteria approved by the Nomination and Remuneration Committee of the Company. The said performance evaluation was then noted by the Board of Directors. The individual Directors were assessed after taking into account their overall contribution and engagement in the growth of the Company, active role in monitoring the effectiveness of Company's Corporate Governance practices and adherence to the Code of Conduct etc. The performance of the Committees of the Board was evaluated after considering the composition, regularity of meetings, independence of the Committees from the Board, their contribution to the effective decisions of the Board, etc.

As per the provisions of Schedule IV of the Act and Regulation 25(3) of the SEBI Listing Regulations, atleast one separate meeting of the Independent Directors of the Company shall be held in a year. However, in order to address the COVID-19 pandemic, Ministry of Corporate Affairs vide General Circular No. 11/ 2020 dated 24th March, 2020, stated that if the Independent Directors of a company have not been able to hold the said meeting for the financial year 2019-20, the same shall not be viewed as a violation. The said circular further mentions that the Independent Directors however, may share their views amongst themselves through telephone or e-mail or any other mode of communication, if they deem it to be necessary. The Company was unable to hold a separate Independent Directors Meeting for the financial year 2019-20, but the Independent Directors in line with the said circular shared their views amongst themselves telephonically.

(7) Remuneration of Directors

(a) Details of the pecuniary relationship or transactions of the Non-Executive Directors of the Company:

The Non-Executive Directors are paid remuneration by way of Commission and Sitting Fees. The details of remuneration paid to Non-Executive Directors for the financial year 2019-20 are as under:

(₹ in Million)

Name	Sitting Fees	Commission	Other Perquisites	Total
*Late Mr. Samprada Singh	-	45.6	-	45.6
#Mr. Akhouri Maheshwar Prasad	0.4	1.8	-	2.2
Mr. Ranjal Laxmana Shenoy	0.3	1.8	-	2.1
Mr. Arun Kumar Purwar	0.2	1.8	-	2.0
Ms. Sudha Ravi	0.2	1.8	-	2.0
Ms. Sangeeta Singh	0.3	1.8	-	2.1
Dr. Dheeraj Sharma	0.1	1.8	-	1.9

* upto 27th July, 2019

upto 15th March, 2020

(b) Criteria of making payments to Non- Executive Directors (NEDs):

The NEDs play a crucial role to the independent functioning of the Board. NEDs bring in external and wider perspective to the decision-making by the Board. They provide leadership and strategic guidance, while maintaining objective judgment. The NEDs also help the Company in ensuring that all legal requirements and corporate governance are complied with and well taken care of.

The responsibilities and obligations imposed on the NEDs have increased manifold in the recent years on account of a number of factors, including the growth in the activities of the Company and the rapid evolution arising out of legal and regulatory provisions and requirements.

Remuneration to the NEDs:

Sitting fees

Non-Executive Independent Directors are paid a sitting fee of ₹ 20,000/- for every Meeting of the Board and/or Committee thereof attended by them.

Commission

Pursuant to the resolution passed by the shareholders of the Company on 16th March, 2015, the Board of Directors are authorised to pay commission to the NEDs and Independent Directors subject to a maximum limit of 2% of the net profits of the Company for each financial year. The said commission is decided each year by the Board of Directors and distributed amongst the Non-Executive/ Independent Directors based on their attendance and contribution to the Board and Committee Meetings as well as time spent on operational matters other than at Meetings.

Apart from sitting fees and commission referred to above and reimbursement of travelling and stay expenses for their attending the Board and Committee Meetings, no payment by way of bonus, pension, incentives, etc. is made to any of the NEDs.

(c) Details of Remuneration to Executive Directors:

The Executive Directors are paid remuneration in accordance with approval of the Board and shareholders and is subject to the limits prescribed under the Act and Remuneration Policy of the Company.

Details of remuneration paid to the Executive Directors during the financial year 2019-20 are as follows:

(₹ in Million)

Terms of Remuneration	Name of Directors					
	Mr. Basudeo N. Singh	Mr. Sandeep Singh	Mr. Dhananjay Kumar Singh	Mr. Balmiki Prasad Singh	Mr. Mritunjay Kumar Singh	*Mr. Sarvesh Singh
Salary as per provisions contained in section 17(1) of the Income Tax Act, 1961.	83.2	63.1	61.3	45.5	61.5	12.0
Value of perquisites u/s 17(2) of the Income Tax Act, 1961	4.5	4.0	5.7	3.3	1.3	0.9
Commission	42.5	-	-	-	-	-
Others (Perquisites and Employer Contribution)	9.2	5.4	5.2	2.7	5.2	0.8
Performance Linked Incentive	-	-	-	-	-	-
Total	139.4	72.5	72.2	51.5	68.0	13.7

* From 11th November, 2019.



Service Contracts, Severance Fees and Notice Period

The appointment and remuneration of the Executive Chairman, Managing Director, Joint Managing Director and other Executive Directors is subject to the provisions of the Act and the resolution passed by the Board of Directors and Members of the Company which cover the terms and conditions of such appointment.

There is no separate provision for payment of severance fee under the resolutions governing the appointment of Executive Chairman, Managing Director, Joint Managing Director and other Executive Directors.

Employee Stock Option Scheme

The Company does not have any Employee Stock Option Scheme for its Directors and Employees.

(8) Stakeholders’ Relationship Committee

The constitution of the Stakeholders’ Relationship Committee is in compliance with the provisions of Section 178 of the Act and Regulation 20 of the SEBI Listing Regulations.

During the year, 4 (four) Stakeholders’ Relationship Committee Meetings were held viz. 29th May, 2019, 12th August, 2019, 11th November, 2019 and 07th February, 2020.

The present composition of the Stakeholders’ Relationship Committee and attendance of Members during the year was as follows:

Name of the Director	Designation in the Committee	No. of Meetings held during Member’s tenure	No. of Meetings attended
Mr. Ranjal Laxmana Shenoy	Chairman	4	4
Mr. Dhananjay Kumar Singh	Member	4	4
*Mr. Akhouri Maheshwar Prasad	Member	4	4
Mr. Mritunjay Kumar Singh	Member	4	4

*Member upto 15th March, 2020

Mr. Manish Narang, President – Legal and Company Secretary was appointed as a Compliance Officer of the Company under Regulation 6 of SEBI Listing Regulations.

Terms of reference of Stakeholders’ Relationship Committee

- (a) Considering and resolving the grievances of security holders of the Company, including complaints related to transfer/transmission of shares, non-receipt of Annual Reports, non-receipt of declared dividends, issue of new/ duplicate certificates, general meetings etc. or any other documents or information to be sent by the Company to its shareholders etc.
- (b) Investigating complaints relating to allotment of shares, approval of transfer or transmission of shares, debentures or any other securities;
- (c) Giving effect to all transfer/ transmission of shares and debentures, dematerialization of shares and rematerialisation of shares, split and issue of duplicate/ consolidated share certificates, allotment and listing of shares, buy back of shares, compliance with all the requirements related to shares, debentures and other securities from time to time;
- (d) Oversee the performance of the registrars and transfer agents of the Company and to recommend measures for overall improvement in the quality of investor services and also to monitor the implementation and

compliance of the code of conduct for prohibition of insider trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and other related matters as may be assigned by the board of directors;

- (e) Review of measures taken for effective exercise of voting rights by shareholders;
- (f) Review of adherence to the service standards adopted by the listed entity in respect of various services being rendered by the Registrar & Share Transfer Agent;
- (g) Review of the various measures and initiatives taken by the listed entity for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/ annual reports/ statutory notices by the shareholders of the company; and
- (h) Carrying out any other functions as prescribed under the SEBI Listing Regulations.

Investor Complaints

There were no complaints remaining unresolved at the beginning of financial year 2019-20. During the financial year ended 31st March, 2020, no complaints were received from investors.

(9) Risk Management Committee

The constitution of the Risk Management Committee is in compliance with the provisions of Regulation 21 of the SEBI Listing Regulations.

During the year, 1 (one) Risk Management Committee Meeting was held on 06th February, 2020.

The present composition of the Risk Management Committee and attendance of Members during the year was as follows:

Name of the Director	Designation in the Committee	No. of Meetings held during Member's tenure	No. of Meetings attended
Mr. Dhananjay Kumar Singh	Chairman	1	1
Mr. Sandeep Singh	Member	1	1
Mr. Mritunjay Kumar Singh	Member	1	1
Ms. Sudha Ravi	Member	1	1
Dr. Dheeraj Sharma	Member	1	1
*Mr. Narendra Kumar Aneja	Member	NA	NA

*Member from 16th March, 2020

Terms of reference of Risk Management Committee

- (a) Laying down risk assessment and minimization procedures and the procedures to inform Board of the same;
- (b) Framing, implementing, reviewing and monitoring the risk management plan and cyber security for the Company; and
- (c) Performing such other activities as may be delegated by the Board of Directors and/or are statutorily prescribed under any law to be attended to by the Risk Management Committee.

(10) Corporate Social Responsibility Committee

The constitution of the Corporate Social Responsibility Committee is in compliance with the provisions of Section 135 of the Act.

During the year, 2 (two) Corporate Social Responsibility Committee Meetings were held viz. 29th May, 2019 and 11th November, 2019.

The present composition of the Corporate Social Responsibility Committee and attendance of Members during the year was as follows:

Name of the Director	Designation in the Committee	No. of Meetings held during the Member's tenure	No. of Meetings attended
Mr. Ranjal Laxmana Shenoy	Chairman	2	2
Mr. Dhananjay Kumar Singh	Member	2	2
Mr. Balmiki Prasad Singh	Member	2	0
Mr. Mritunjay Kumar Singh	Member	2	2
Mr. Arun Kumar Purwar	Member	2	2

Terms of reference of the Corporate Social Responsibility Committee

- (a) Formulate and recommend to the Board of Directors, a "Corporate Social Responsibility Policy" which shall indicate the activities to be undertaken by the Company as specified in Schedule VII of the Act;
- (b) Review and recommend the amount of expenditures to be incurred on the activities to be undertaken by the Company;
- (c) Monitor the Corporate Social Responsibility policy of the Company from time to time;
- (d) Any other matter as the Corporate Social Responsibility Committee may deem appropriate after the approval of the Board of Directors or as may be directed by the Board of Directors from time to time.



(11) General Body Meetings

(i) Location and time of the last three Annual General Meetings (AGM) held are as follows:

Year	Meeting	Location	Date	Time	Special Resolutions passed
2016-17	43 rd AGM	Nehru Centre Auditorium, Dr. Annie Besant Road, Worli, Mumbai 400 018.	8 th September, 2017	10.30 a.m.	NIL
2017-18	44 th AGM	Nehru Centre Auditorium, Dr. Annie Besant Road, Worli, Mumbai 400 018.	31 st August, 2018	10.30 a.m.	NIL
2018-19	45 th AGM	Nehru Centre Auditorium, Dr. Annie Besant Road, Worli, Mumbai 400 018.	27 th August, 2019	10.30 a.m.	<ol style="list-style-type: none"> Approval for re-appointment of Mr. Basudeo N. Singh (DIN: 00760310) as Executive Chairman of the Company for a period of one (1) year w.e.f. 01st April, 2019 upto 31st March, 2020. Approval for appointment of Mr. Basudeo N. Singh (DIN: 00760310) as Non-Executive Director designated as Chairman of the Company for a period of five (5) consecutive years w.e.f. 01st April, 2020 upto 31st March, 2025. Approval for re-appointment of Mr. Ranjal Laxmana Shenoy (DIN: 00074761) as an Independent Director for the second term of five (5) consecutive years w.e.f. 16th March, 2020 upto 15th March, 2025. Approval for re-appointment of Mr. Arun Kumar Purwar (DIN: 00026383) as an Independent Director for the second term of five (5) consecutive years w.e.f. 13th July, 2020 upto 12th July, 2025. Approval for re-appointment of Ms. Sangeeta Singh (DIN: 06920906) as an Independent Director for the second term of five (5) consecutive years w.e.f. 13th July, 2020 upto 12th July, 2025. Approval of re-appointment of Ms. Sudha Ravi (DIN: 06764496) as an Independent Director for the second term of five (5) consecutive years w.e.f. 13th July, 2020 upto 12th July, 2025.



(ii) **Extraordinary General Meeting (EGM)**

No Extraordinary General Meeting was held during the financial year.

No special resolution is proposed to be passed through postal ballot till the date of ensuing AGM to be held on 18th August, 2020.

(iii) **Details of Special Resolution passed through Postal Ballot, the person who conducted the Postal Ballot exercise and details of the voting pattern**

During the financial year 2019-20, the Company vide postal ballot notice dated 07th February, 2020 passed the special resolution for re-appointment and increase in remuneration of Mr. Basudeo N. Singh (DIN: 00760310) as an Executive Chairman of the Company for the term of five consecutive years w.e.f. 01st April, 2020 to 31st March, 2025.

Person Conducting the Postal Ballot Exercise

Mr. Manish Narang, President – Legal, Company Secretary & Compliance Officer was appointed as person responsible for the entire postal ballot process. CS Manish L. Ghia, Partner of M/s. Manish Ghia & Associates, Company Secretaries was appointed as the Scrutiniser for conducting the postal ballot voting process in a fair and transparent manner. CS Manish L. Ghia, Practicing Company Secretary conducted the postal ballot process and submitted the report to the Company.

Procedure followed for Postal Ballot

- In compliance with Regulation 44 of the SEBI Listing Regulations and Section 108, 110 and other applicable provisions of the Act read with the rules made thereunder, the Company provided electronic voting facility to all its Members, to enable them to cast their votes electronically. The Company engaged the services of Central Depository Services (India) Limited (CDSL) for the purpose of providing e-voting facility. The Members had the option to vote either by physical ballot or e-voting.
- The Company dispatched the postal ballot notice dated 07th February, 2020, containing the draft resolution together with the explanatory statement, postal ballot forms and self-addressed business reply envelopes to the Members whose names appeared in the register of members / list of beneficiaries as on cut-off date i.e. Friday, 28th February, 2020. The Company also published a notice in the newspaper declaring the details of completion of dispatch and other requirements as mandated under the Act and applicable rules.
- The Members who opted for the e-voting could vote from Friday, 06th March, 2020 at 9.00 a.m. to Saturday, 04th April, 2020 at 5.00 p.m. Members desiring to exercise their votes by physical postal ballot forms were requested to return the forms duly completed and signed, to the Scrutiniser on or before the close of business hours on Saturday, 04th April, 2020.
- The Scrutiniser submitted his report on Monday, 06th April, 2020, after the completion of scrutiny.
- The result of the postal ballot was declared on Monday, 06th April, 2020. The Resolution passed by requisite majority, was deemed to have been passed on the last date specified by the Company for receipt of duly completed postal ballot forms or e-voting i.e. Saturday, 04th April, 2020.
- The result of the postal ballot is available on the website of the Company at www.alkemlabs.com, besides being communicated to Stock Exchanges, Depository and Registrar and Share Transfer Agent.
- Details of voting pattern:

Special Resolution	No. of votes polled	Votes cast in favour of the Resolution (no. & %)	Votes cast against the Resolution (no. & %)
1. Re-appointment and increase in remuneration of Mr. Basudeo N. Singh (DIN: 00760310) as an Executive Chairman of the Company for the term of five consecutive years w.e.f. 01 st April, 2020 to 31 st March, 2025	73,913,960	67,295,603 (91.05%)	6,618,357 (8.95%)

(12) Means of Communication

The Company, from time to time and as may be required, communicates with its shareholders and investors through multiple channels of communications such as dissemination of information on the online portal of the Stock Exchanges, press releases, the Annual Reports and uploading relevant information on its website.

- (i) Financial Results and Statements:** The unaudited quarterly results are announced within forty five days from the end of the quarter. The audited annual results are announced within sixty days from the closure of financial year as required under SEBI Listing Regulations. The aforesaid financial results are communicated to the Stock Exchanges within thirty minutes from the close of the Board Meeting at which these were considered and approved. The results are generally published in Business Standard, national daily newspaper and in Mumbai Lakshadweep, which is a regional (Marathi) daily newspaper.

The audited financial statements form part of the Annual Report which is sent to the Members within the statutory period and well in advance of the AGM. The Annual Report of the Company, the quarterly / half yearly and the yearly financial results and financial

statements and the press releases of the Company are also disseminated on the Company's website www.alkemlabs.com and can be downloaded.

- (ii) Presentations, Press Releases:** The presentations on the performance of the Company and press releases are placed on the Company's website immediately after these are communicated to the Stock Exchanges for the benefit of the Institutional Investors and analysts and other shareholders.
- (iii) Material Information:** The Company discloses to the Stock Exchanges, all information required to be disclosed under Regulation 30 read with Part A of Schedule III of the SEBI Listing Regulations including material information having a bearing on the performance / operations of the listed entity or other price sensitive information.
- (iv) Online filing:** All information is filed electronically on BSE's online Portal – BSE Corporate Compliance & Listing Centre (Listing Centre) and on NSE Electronic Application Processing System (NEAPS), online portal of The National Stock Exchange of India Limited.
- (v) SCORES:** Facility has been provided by SEBI for investors to place their complaints / grievances on a



centralized web-based complaints redressal system viz. SEBI Complaints Redress System (SCORES). The salient features of this system are: Centralized database of all complaints, online upload of Action Taken Reports (ATRs) by the concerned companies and online viewing by investors of actions taken on the complaint and its current status.

(13) General Shareholder Information

- (a) The 46th AGM of the Members of the Company will be held on Tuesday, 18th August, 2020 at 11.00 a.m. through video conferencing.
- (b) Financial year: 01st April, 2019 to 31st March, 2020.
- (c) Dividend payment date: Final dividend for the financial year 2018-19 was paid during the financial year 2019-20 on and from 29th August, 2019.

Interim dividend for the financial year 2019-20 was paid on and from 18th February, 2020. Record date for the purpose of payment of final dividend for the financial year ended 31st March, 2020 shall be 11th August, 2020.

Final dividend on equity shares as recommended by the Directors for the year ended 31st March, 2020, if approved at the AGM, will be paid on and from 21st August, 2020.

(d) Due dates for Transfer of Unclaimed Dividend to the Investor Education and Protection Fund (IEPF)

Year	Dividend	Date of Declaration	Due for transfer to IEPF
2015-16	Second Interim	09.03.2016	14.04.2023
2016-17	Interim	11.11.2016	13.12.2023
2016-17	Final	08.09.2017	13.10.2024
2017-18	Interim	09.02.2018	13.03.2025
2017-18	Final	31.08.2018	01.10.2025
2018-19	Interim	08.02.2019	13.03.2026
2018-19	Final	27.08.2019	01.10.2026
2019-20	Interim	07.02.2020	11.03.2027

(e) Listing on Stock Exchanges

The Company's shares are listed on the following Stock Exchanges and the annual listing fees has been paid to each of such Stock Exchanges:



Name and Address of the Stock Exchanges	Stock Code/ Scrip Code	ISIN for NSDL / CDSL (Dematerialized shares)
BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001	539523	INE540L01014
The National Stock Exchange of India Limited, Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051	ALKEM	

(f) Market Price data

Month	BSE			NSE		
	High Price (₹)	Low Price (₹)	Number of Shares Traded	High Price (₹)	Low Price (₹)	Number of Shares Traded
April 2019	1,789.95	1,688.00	725,775	1,783.95	1,695.10	1,449,097
May 2019	1,815.50	1,674.00	25,503	1,987.20	1,670.00	557,057
June 2019	1,840.00	1,660.35	20,030	1,844.00	1,661.00	498,027
July 2019	1,836.45	1,669.50	13,308	1,836.00	1,670.00	649,368
August 2019	1,840.00	1,662.30	28,556	1,844.90	1,660.00	963,049
September 2019	1,997.40	1,770.00	109,980	1,997.05	1,783.85	886,012
October 2019	2,029.80	1,879.35	11,281	2,027.90	1,873.00	705,902
November 2019	2,149.00	1,945.00	76,505	2,150.00	1,940.80	1,495,781
December 2019	2,108.00	1,957.30	54,507	2,107.00	1,958.00	721,439
January 2020	2,404.40	2,010.00	85,313	2,405.00	2,006.90	2,435,119
February 2020	2,720.00	2,325.00	101,878	2,716.90	2,322.05	2,734,379
March 2020	2,669.15	1,950.00	160,989	2,670.00	1,881.30	2,185,832

(g) Performance in comparison to broad based indices

Month	BSE		NSE	
	Alkem Share Price (₹)	S&P BSE Sensex	Alkem Share Price (₹)	Nifty 50
April 2019	1,719.95	39,031.55	1,718.35	11,748.15
May 2019	1,790.05	39,714.20	1,794.35	11,922.80
June 2019	1,668.65	39,394.64	1,669.00	11,788.85
July 2019	1,736.85	37,481.12	1,741.95	11,118.00
August 2019	1,816.85	37,332.79	1,817.70	11,023.25
September 2019	1,903.85	38,667.33	1,905.10	11,474.45
October 2019	1,989.85	40,129.05	1,997.70	11,877.45
November 2019	2,025.20	40,793.81	2,029.10	12,056.05
December 2019	2,013.55	41,253.74	2,013.90	12,168.45
January 2020	2,394.30	40,723.49	2,397.65	11,962.10
February 2020	2,627.90	38,297.29	2,625.50	11,201.75
March 2020	2,328.85	29,468.49	2,325.85	8,597.75





(h) Registrar to an issue and Share Transfer Agent:

Link Intime India Private Limited, C 101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400083 are Company's Registrar and Share Transfer Agent and their registration number is INR000004058.

(i) Shares Transfer System:

Regulation 40 of the SEBI Listing Regulations as amended vide SEBI Circular No. SEBI/LAD-NRO/ GN/2018/24 dated 8th June, 2018 mandated the transfer (except in case of transmission or transposition) of securities only in dematerialized form with a depository. Pursuant thereto, Company had sent letters to the sole shareholder holding shares in physical form advising dematerialization of its holding. As on 31st March, 2020, the said shareholder has neither dematerialized its holding nor transferred any shares during the year under review.

(j) Distribution of shareholding

Distribution of shareholding as on 31st March, 2020

Shareholding of Nominal Shares	No. of Folios	% of Total	Total No. of Shares	% of Total
1-1000	75372	99.35	2682275	2.24
1001-2000	148	0.20	211011	0.18
2001-4000	82	0.11	226789	0.19
4001-6000	32	0.04	153722	0.13
6001-8000	18	0.02	131123	0.11
8001-10000	15	0.02	133413	0.11
10001-20000	51	0.07	755102	0.63
Above 20000	145	0.19	115271565	96.41
Total	75863	100.00	119565000	100.00
Physical Mode	1	0.00*	1	0.00*
Electronic Mode	75862	99.99	119564999	99.99

* Negligible

Shareholding Pattern as on 31st March, 2020

Category	Total Shares	Percentage Total
Central Government	288081	0.24
Clearing Members	98112	0.08
Other Bodies Corporate	930132	0.78
Financial Institutions/ Banks	394063	0.33
Insurance Companies	2801172	2.34
Hindu Undivided Family	159549	0.13
Mutual Funds	10217665	8.55
Non Resident Indians	130884	0.11
Non Resident (Non Repatriable)	54387	0.05
Public	20984292	17.55
Promoters	78774497	65.88
Trusts	4051	0.00*
Foreign Portfolio Investors	4348472	3.64
Alternate Investment Funds	379643	0.32
Total	119565000	100

* Negligible

(k) Dematerialization of shares and liquidity

About 99.99% of the Equity Shares of the Company have been dematerialized up to 31st March, 2020.

(l) Reconciliation of Share Capital Audit

As required by SEBI, quarterly audit of the Company's share capital is being carried out by a Practising Company Secretary (PCS) with a view to reconcile the total share capital admitted with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) and held in physical form, with the issued and listed capital. The PCS Certificate in regard to the same is submitted to BSE Limited and The National Stock Exchange of India Limited and is also placed before Stakeholders' Relationship Committee and the Board of Directors.

03-21	Corporate Overview
22-93	Statutory Reports
94-228	Financial Statements

(m) The Company has not issued any Global Depository Receipts (GDR) or American Depository Receipts (ADR) or Warrants or any convertible instruments.

(n) Foreign Currency Hedging Activities

The Board of Directors of the Company has approved a "Treasury Policy" to manage the treasury risks of the Company within its risk appetite, which is derived from the business exigency and corporate policy. The Hedging activities of the Company shall be a mix of Natural Hedges, Packing Credit and Forwards & Options so that risk can be minimized while capturing opportunity wherever possible.

(o) Plant locations

1. Unit I & II Daman, India.
2. Mandva, Gujarat, India.
3. Ankleshwar, Gujarat, India.
4. Unit I & II, Baddi, Himachal Pradesh, India.
5. Kumrek, East Sikkim, India.
6. Alkem Health Science, (Unit of the Company) Unit I, II & III, Samardung, South Sikkim, India.
7. California, U.S.A.
8. Missouri, U.S.A.
9. Indchemie Health Specialities Private Limited, Somnath, Daman, India.
10. Indchemie Health Specialities Private Limited, Amaliya, Daman, India.
11. Indchemie Health Specialities Private Limited, Baddi, Himachal Pradesh, India.
12. Unit I & II, Indchemie Health Specialities Private Limited, Kumrek, East Sikkim, India.
13. Cachet Pharmaceuticals Private Limited, Baddi, Himachal Pradesh, India.
14. Alkem Labs Ltd, Unit 5, South Sikkim, India.
15. Alkem Labs Ltd., S.E.Z., Indore, Madhya Pradesh, India.
16. Enzene Biosciences Limited, Chakan, Pune, Maharashtra, India.

(p) Address for correspondence

Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai – 400 013.
Tel No: +91 22 3982 9999; Fax No: +91 22 2495 2955

Communication by E-mail:

For transfer / transmission / subdivision / demat / loss of shares / dividend / general inquiries and investor grievance: investors@alkem.com

List of Credit Ratings

Credit Ratings of Company's outstanding instruments:

Instrument Type	Rating Agency	Credit Rating
Commercial Paper	CRISIL India Ratings (Fitch)	CRISIL A1+ IND A1+

Credit Ratings of Company's outstanding facilities:

Rating	Rating Agency	Credit Rating	Outlook
Long Term Rating	CRISIL	CRISIL AA+	Stable
Short Term Rating	CRISIL	CRISIL A1+	-

(14) Disclosures

(a) Related Party Transactions

The Company has adequate procedures for purpose of identification and monitoring of related party transactions. There were no materially significant transactions with related parties during the financial year which were in conflict with the interest of the Company. All related party transactions which were on arm's length basis in the ordinary course of business were periodically placed before the Audit Committee and the Board for review and approval, as appropriate. The details of related party transactions are provided in notes to financial statements of this annual report. The policy on related party transaction has been placed on the Company's website and can be accessed through https://www.alkemlabs.com/pdf/policies/84051713915915Policy_on_Related_Party_Transactions.pdf

(b) Strictures and Penalties

No strictures or penalties have been imposed on the Company by the Stock Exchanges or by the Securities and Exchange Board of India (SEBI) or by any statutory authority on any matters related to capital markets during the last three years.

(c) Whistle Blower Policy

The Company requires its Officers and Employees to observe high standards of business and personal ethics in the conduct of their duties and responsibilities. For this purpose the Board of Directors of the Company has adopted "Whistle Blower Policy" to encourage and enable employees and volunteers of the Company to report any action or suspected action taken within the Company that is illegal, fraudulent or in violation of any adopted policy and to build and strengthen a culture of transparency and trust within the organization. The person making a report of the violation can keep his/her identity anonymous and choose to submit the violation report on a confidential basis. If an individual reasonably believes that a violation has occurred, the individual is encouraged to share his or her questions, concerns, suggestion or complaints



to person designated by the Company. Specific telephone number and email ID is mentioned in the Whistle Blower Policy. In addition to the above, under exceptional circumstances a complainant can complain directly to the Chairman of the Audit Committee. No personnel of the Company has been denied access to either the Designated Person or to the Audit Committee. The Whistle blower Policy has been placed on the Company's website and can be accessed through https://www.alkemlabs.com/pdf/policies/961507913Whistle_Blower_Policy.pdf

(d) The Company has formulated Risk Management Plan and all the directors are informed about risk assessment and minimization procedures.

(e) Subsidiary Companies

The Board of Directors of the Company in its Meeting held on 30th May, 2019, reviewed the list of material subsidiaries of the Company and qualified Ascend Laboratories LLC, USA ("Ascend"), wholly owned subsidiary of the Company contributing 24.4% to the total consolidated income of the Company as its material subsidiary. Further, in accordance with Regulation 24 (1) of SEBI Listing Regulations, Mr. Ranjal Laxmana Shenoy, Independent Director of the Company has been appointed on the Board of Ascend. The Company's policy on "material subsidiary" is placed on the Company's website and can be accessed through weblink https://www.alkemlabs.com/pdf/policies/1594553244Policy_for_determining.pdf

(f) The Company does not undertake any Commodity hedging activities.

(g) The Company has not raised any funds by way of preferential allotment or qualified institutions placement as specified under Regulation 32 (7A) of SEBI Listing Regulations.

(h) The Company has obtained a certificate dated 05th June, 2020 from M/s Manish Ghia & Associates, Practising Company Secretaries, certifying that none of the Directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as director of companies by the SEBI/ Ministry of Corporate Affairs or any such statutory authority.

(i) The Board has accepted all the recommendations of the Committees of the Board.

(j) Total fees of ₹ 23.9/- Million was paid for all services provided to the Company and its subsidiaries, on a consolidated basis, to M/s B S R & Co., Statutory Auditors and all entities in the network firm/network entity of which the statutory auditor is a part.

(k) Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

a. number of complaints filed during the financial year : NA

b. number of complaints disposed of during the financial year : NA

c. number of complaints pending as on end of the financial year : NA

(15) Compliance with Discretionary Requirements

i. Chairman Emeritus maintained office at the Company's expense till 27th July, 2019.

ii. Half yearly, yearly and quarterly financial statements are published in the newspapers and are also posted on the Company's website.

iii. The Company's financial statement for the financial year ended 31st March, 2020 does not contain any modified audit opinion.

iv. Internal Auditors directly report to the Audit Committee.

(16) There are no Equity Shares of the Company in the demat suspense or unclaimed suspense account.

(17) The Company has complied with the requirements specified in Regulations 17 to 27 and Clauses (b) to (i) of Regulation 46 (2) of the SEBI Listing Regulations.

For and on behalf of the Board
Alkem Laboratories Limited

Basudeo N. Singh

Executive Chairman

DIN: 00760310

Place: Mumbai

Date: 05th June, 2020